AgingResearch.NewsJoin free

OMEICOS Therapeutics

CompanyGermanyFounded 2013

OMEICOS Therapeutics develops one asset, in phase 2 (OMT-28 in primary mitochondrial disease). Mostly small molecule acting on Mitochondrial biogenesis (PGC-1α), SIRT1 and inflammation; based in Germany, founded in 2013.

1
Asset
Furthest stage
Phase 2
3
Trials
0
Signals

Pipeline

1

  • OMT-28

    Activates the AMPK/SIRT1/PGC1-alpha axis to reduce mitochondrial dysfunction, oxidative stress and inflammation.

    Phase 2, Small molecule, Mitochondrial biogenesis (PGC-1α), SIRT1, primary mitochondrial disease, chronic inflammation in coronary artery disease (Preclinical)

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Trials3
  • People12
  • Similar companies6

Intelligence